Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:52:29.531Z.
Calculation as of: 2026-10-06T19:52:29.531Z.
Quote observation: 2026-10-06T19:50:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 48f0cd224d3c7dd52ecd2cde696dbbeed4cc913852df97ed5052446ca25b90ee
PEG RATIO
N/A
Hyperfine, Inc.
Market Cap
$73.86M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Hyperfine, Inc. (HYPR) | $73.86M | N/A |
| Pulmonx Corporation (LUNG)vs › | $74.90M | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $72.60M | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $75.82M | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $73.10M | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $75.98M | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.02M | N/A |
| Outset Medical, Inc. (OM)vs › | $76.75M | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $77.72M | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $77.73M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
